Last reviewed · How we verify

NCT05213988

Effects on Glucose Homeostasis of Changes in Plasma Lipoproteins Induced by Nutritional and Pharmacologic Strategies

Status unknown NA Last updated 28 January 2022
What this trial tests

NA trial testing Intermittent Fasting in Glucose Metabolism Disorders in 50 participants. Status unknown.

Timeline
30 July 2018
Primary endpoint
1 January 2025
1 January 2025

Quick facts

Lead sponsorAzienda Ospedaliero, Universitaria Pisana
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposebasic science
Enrollment50
Start date30 July 2018
Primary completion1 January 2025
Estimated completion1 January 2025
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

Azienda Ospedaliero, Universitaria Pisana — full company profile →

Who can join

Adults 18 to 65, any sex, with Glucose Metabolism Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators aim to examine the impact of changes in plasma lipoproteins induced by nutritional and pharmacological interventions on glucose homeostasis

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Intermittent Fasting

Trials testing the same drug.

Other recruiting trials for Glucose Metabolism Disorders

Currently open trials in the same condition.

Other Azienda Ospedaliero, Universitaria Pisana trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05213988.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing